European approach to antibody-based immunotherapy of melanomaALTOMONTE, Maresa; MAIO, Michele.Seminars in oncology. 2002, Vol 29, Num 5, pp 471-478, issn 0093-7754Article

Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugsMURGO, Anthony J.Seminars in oncology. 2005, Vol 32, Num 5, pp 458-464, issn 0093-7754, 7 p.Article

Clinical development of decitabine as a prototype for an epigenetic drug programROSENFELD, Craig S.Seminars in oncology. 2005, Vol 32, Num 5, pp 465-472, issn 0093-7754, 8 p.Article

Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine)MOMPARLER, Richard L.Seminars in oncology. 2005, Vol 32, Num 5, pp 443-451, issn 0093-7754, 9 p.Article

Epigenetic drugs : A longstanding storyDE VOS, Dick.Seminars in oncology. 2005, Vol 32, Num 5, pp 437-442, issn 0093-7754, 6 p.Article

Melanoma I: American and European perspectives on diagnosis and treatmentMCCLAY, Edward F; MAIO, Michele.Seminars in oncology. 2002, Vol 29, Num 4, issn 0093-7754, 106 p.Serial Issue

Melanoma II : American and European Perspectives on Diagnosis and TreatmentMCCLAY, Edward F; MAIO, Michele.Seminars in oncology. 2002, Vol 29, Num 5, issn 0093-7754, 116 p.Serial Issue

Biomolecular strategies for therapeutic intervention in cancerGIORDANO, Antonio; MAIO, Michele.Oncogene (Basingstoke). 2003, Vol 22, Num 42, issn 0950-9232, 193 p.Serial Issue

Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?ALTOMONTE, Maresa; FONSATTI, Ester; VISINTIN, Alberto et al.Oncogene (Basingstoke). 2003, Vol 22, Num 42, pp 6564-6569, issn 0950-9232, 6 p.Article

Epigenetic targets for immune intervention in human malignanciesMAIO, Michele; CORAL, Sandra; FRATTA, Elisabetta et al.Oncogene (Basingstoke). 2003, Vol 22, Num 42, pp 6484-6488, issn 0950-9232, 5 p.Article

Epigenetic drugs as immunomodulators for combination therapies in solid tumorsSIGALOTTI, Luca; FRATTA, Elisabetta; CORAL, Sandra et al.Pharmacology & therapeutics (Oxford). 2014, Vol 142, Num 3, pp 339-350, issn 0163-7258, 12 p.Article

Epigenetic changes in solid and hematopoietic tumorsTOYOTA, Minoru; ISSA, Jean-Pierre J.Seminars in oncology. 2005, Vol 32, Num 5, pp 521-531, issn 0093-7754, 11 p.Article

Adjuvant therapy for patients with high-risk malignant melanomaMCCLAY, Edward F.Seminars in oncology. 2002, Vol 29, Num 4, pp 389-399, issn 0093-7754Article

Melanoma vaccinesMINEV, Boris R.Seminars in oncology. 2002, Vol 29, Num 5, pp 479-493, issn 0093-7754Article

Cancer epigeneticsMOMPARLER, Richard L.Oncogene (Basingstoke). 2003, Vol 22, Num 42, pp 6479-6483, issn 0950-9232, 5 p.Article

Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptorSURMACZ, Eva.Oncogene (Basingstoke). 2003, Vol 22, Num 42, pp 6589-6597, issn 0950-9232, 9 p.Article

The revised american joint committee on cancer staging system for melanomaTHOMPSON, John A.Seminars in oncology. 2002, Vol 29, Num 4, pp 361-369, issn 0093-7754Article

Targeting the epigenome for the treatment and prevention of lung cancerSCHRUMP, David S; NGUYEN, Dao M.Seminars in oncology. 2005, Vol 32, Num 5, pp 488-502, issn 0093-7754, 15 p.Article

Epigenetic treatment of hematopoietic malignancies : In vivo targets of demethylating agentsCLAUS, Rainer; ALMSTEDT, Maika; LÜBBERT, Michael et al.Seminars in oncology. 2005, Vol 32, Num 5, pp 511-520, issn 0093-7754, 10 p.Article

Axis of evil: molecular mechanisms of cancer metastasisBOGENRIEDER, Thomas; HERLYN, Meenhard.Oncogene (Basingstoke). 2003, Vol 22, Num 42, pp 6524-6536, issn 0950-9232, 13 p.Article

Small-molecule cyclin-dependent kinase modulatorsSENDEROWICZ, Adrian M.Oncogene (Basingstoke). 2003, Vol 22, Num 42, pp 6609-6620, issn 0950-9232, 12 p.Article

Gene-based therapy of malignant melanomaSCHADENDORF, Dirk.Seminars in oncology. 2002, Vol 29, Num 5, pp 503-512, issn 0093-7754Article

Clinical Studies With Anti-CTLA-4 Antibodies in Non-melanoma Indications : Immunologic checkpoints for cancer treatment: from scientific rationale to clinical applicationCALABRO, Luana; DANIELLI, Riccardo; SIGALOTTI, Luca et al.Seminars in oncology. 2010, Vol 37, Num 5, pp 460-467, issn 0093-7754, 8 p.Article

The Emerging Toxicity Profiles of Anti-CTLA-4 Antibodies Across Clinical Indications : Immunologic checkpoints for cancer treatment: from scientific rationale to clinical applicationDI GIACOMO, Anna Maria; BIAGIOLI, Maurizio; MAIO, Michele et al.Seminars in oncology. 2010, Vol 37, Num 5, pp 499-507, issn 0093-7754, 9 p.Article

Page / 4